Innovation, Access, and the Future of Cardiac Care
MD Newsline
In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical...
info_outline
From Awareness to Action: Cancer Prevention & Patient Empowerment
MD Newsline
In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure,...
info_outline
AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps
MD Newsline
In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also...
info_outline
How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer
MD Newsline
In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System’s Role in...
info_outline
Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy
MD Newsline
In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the...
info_outline
Vitamin D, Epstein-Barr Virus, and MS Risk
MD Newsline
In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the...
info_outline
Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment
MD Newsline
In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on...
info_outline
How Ultra-Processed Food Impacts MS Progression
MD Newsline
In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of...
info_outline
Biomarkers in Multiple Sclerosis: Tracking Disease Progression
MD Newsline
In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and...
info_outline
Optic Neuritis, MS Differentials, and Modern Treatment Pathways
MD Newsline
In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in...
info_outlineIn this episode of MD Newsline, Dr. Eleonora Teplinksy, a breast and gynecologic medical oncologist at Valley Health System and clinical assistant professor at the Icahn School of Medicine at Mount Sinai, shares key updates from the ASCO annual meeting. She discusses transformative clinical trials that are reshaping the landscape of metastatic breast cancer treatment across subtypes including hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
Dr. Teplinksy highlights the promise of early mutation detection, the potential of antibody-drug conjugates, and the power of liquid biopsies. She also addresses pressing concerns around clinical trial diversity, treatment access, and the need for multidisciplinary care.
Episode Highlights:
Early Detection in HR+ Breast Cancer: The SERENA-6 Trial The SERENA-6 trial investigates whether switching to camizestrant—an oral SERD—upon early ESR1 mutation detection via liquid biopsy (before radiographic progression) improves progression-free survival. The study showed a 56% reduction in disease progression risk. However, issues around FDA approval, cost, testing frequency, and racial representation remain key concerns.
Advancing Triple-Negative Breast Cancer Care: ASCENT-04 The ASCENT-04 trial evaluates sacituzumab govitecan plus pembrolizumab vs. standard chemo-immunotherapy in PD-L1+ patients. Results revealed improved PFS (7.8 to 11.2 months), showing promise for first-line triple-negative treatment, though insurance coverage may delay clinical implementation.
HER2+ Breast Cancer Innovation: DESTINY-Breast09 This trial demonstrated that combining T-DXd with pertuzumab improved PFS from 26.9 to 40 months, suggesting a new standard for HER2+ metastatic breast cancer. Still, side effects like interstitial lung disease and lack of clarity on endocrine therapy integration must be addressed.
Real-World Barriers: Cost, Toxicity, and Care Access Dr. Teplinksy emphasizes challenges patients face—from time toxicity to insurance denials—and calls for thoughtful side-effect management and patient-centered treatment planning.
Multidisciplinary Collaboration and Future of AI in Oncology She underlines the role of interdisciplinary care and the need to bridge gaps across specialties. With AI and machine learning emerging, Dr. Teplinksy envisions more tailored treatments driven by biomarkers and real-world insights.
Key Takeaway
Dr. Teplinksy stresses the importance of early intervention, clinical trial equity, and multidisciplinary care in improving breast cancer outcomes. As the field embraces antibody-drug conjugates and AI-driven personalization, collaboration and access must evolve in step.
ResourcesWebsite: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Eleonora Teplinksy: Here
Hosted on Acast. See acast.com/privacy for more information.